ICAM1 and Familial prostate cancer: CD54 upregulation is currently used as a surrogate for assessing human APC activation and also as a potency measure of sipuleucel-T, an approved active cellular immunotherapy product designed to stimulate an immune response against prostate cancer [25,30].